Figure 2
From: Vitamin D3 deficiency and osteopenia in spastic paraplegia type 5 indicate impaired bone homeostasis
Baseline levels of serum markers assessed by ELISA in hereditary spastic paraplegia type 5 (SPG5) patients and matched controls (CO) (N = 14, per group). For displaying vitamin D3 metabolism, basal levels of (A) 25(OH) vitamin D3 and (B) 1,25(OH)2 vitamin D3 were determined. As regulators of osteoblast and osteoclast function, basal levels of (C) sclerostin, as well as (D) the ratio of soluble receptor activator of nuclear factor-κB ligand (sRANKL), and its antagonist osteoprotegerin (OPG), were determined. Osteoblast function is displayed by (E) bone alkaline phosphatase (BAP) and associated collagen formation by (F) N-terminal propeptide of human procollagen type I (PINP) levels. Osteoclast function is displayed by (G) tartrate-resistant acidic phosphatase 5b (TRAP5b) and associated collagen degradation by (H) cross-linked N-telopeptide of type I collagen (NTX). Each sample was measured in duplicates (n = 2). Both groups were compared using the non-parametric Wilcoxon matched-pairs signed-rank test (2-tailed), with p < 0.1 being specified in the figure.
